fstop123/Getty Images(NEW YORK) Well before a federal judge in Texas issued his ruling on the abortion drug mifepristone, abortion providers across the country said they had been preparing for what they called a "worst-case scenario."
In his April 7 decision, Judge Matthew Kacsmaryk of the Northern District of Texas ruled in favor of Alliance Defending Freedom a conservative Christian legal advocacy group that asked him to reverse the U.S. Food and Drug Administration s approval of mifepristone, an oral medication typically taken with misoprostol to end a pregnancy.
The advocacy group s lawsuit said mifepristone is unsafe and that the FDA didn t study it closely enough before approving its use. The FDA and mainstream medical doctors insist this isn’t true, and that there have been no safety concerns during the 23 years the drug has been on the market.
Now, Kacsmaryk s issuing of a nationwide injunction on mifepristone set to take effect by Friday may impact as
(NEW YORK) Well before a federal judge in Texas issued his ruling on the abortion drug mifepristone, abortion providers across the country said they had been preparing for what they called a "worst-case scenario." In his April 7 decision, Judge Matthew Kacsmaryk of the Northern District of Texas ruled in favor of Alliance Defending
fstop123/Getty Images(NEW YORK) Well before a federal judge in Texas issued his ruling on the abortion drug mifepristone, abortion providers across the country said they had been preparing for what they called a "worst-case scenario."
In his April 7 decision, Judge Matthew Kacsmaryk of the Northern District of Texas ruled in favor of Alliance Defending Freedom a conservative Christian legal advocacy group that asked him to reverse the U.S. Food and Drug Administration s approval of mifepristone, an oral medication typically taken with misoprostol to end a pregnancy.
The advocacy group s lawsuit said mifepristone is unsafe and that the FDA didn t study it closely enough before approving its use. The FDA and mainstream medical doctors insist this isn’t true, and that there have been no safety concerns during the 23 years the drug has been on the market.
Now, Kacsmaryk s issuing of a nationwide injunction on mifepristone set to take effect by Friday may impact as